Design Therapeutics (DSGN) EBIT (2020 - 2026)
Design Therapeutics (DSGN) reported EBIT of -$19.7 million for Q1 2026, up 3.49% on a YoY basis from -$19.0 million in Q1 2025, and down 8.46% sequentially from -$18.2 million in Q4 2025.
Design Therapeutics (DSGN) EBIT (2020 - 2026) Analysis & Trends
Design Therapeutics (DSGN) has 7 years of EBIT data on file, last reported at -$19.7 million in Q1 2026.
- For the quarter ending Q1 2026, EBIT rose 3.49% year-over-year to -$19.7 million; the trailing twelve-month figure through Mar 2026 stood at -$78.8 million (down 15.14% YoY), and the FY2025 full-year result was -$79.5 million, down 27.39% from the prior year.
- EBIT slipped to -$19.7 million in Q1 2026, from -$18.2 million in the prior quarter.
- In the past five years, EBIT ranged from a high of -$13.4 million in Q1 2022 to a low of -$22.6 million in Q2 2023.
- A 5-year average of -$18.1 million and a median of -$18.8 million in 2023 frame the typical range for EBIT.
- Across the five-year window, EBIT tumbled 135.39% in 2022 and jumped 33.49% in 2024, its largest moves.
- Tracing DSGN's EBIT over 5 years: stood at -$19.4 million in 2022, then advanced by 22.02% to -$15.1 million in 2023, then declined by 10.4% to -$16.7 million in 2024, then dropped by 8.84% to -$18.2 million in 2025, then dropped by 8.46% to -$19.7 million in 2026.
- Business Quant data shows DSGN's EBIT at -$19.7 million in Q1 2026, -$18.2 million in Q4 2025, and -$19.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -15.76 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 249.90 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 394.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -445.22 Mn |
| 10 | Design Therapeutics | 725.54 Mn | 502.72 Mn | - | -19.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.71 Mn |
| Dec 31, 2025 | -18.17 Mn |
| Sep 30, 2025 | -19.31 Mn |
| Jun 30, 2025 | -21.57 Mn |
| Mar 31, 2025 | -20.42 Mn |
| Dec 31, 2024 | -16.69 Mn |
| Sep 30, 2024 | -16.25 Mn |
| Jun 30, 2024 | -15.04 Mn |
| Mar 31, 2024 | -14.40 Mn |
| Dec 31, 2023 | -15.12 Mn |
| Sep 30, 2023 | -18.82 Mn |
| Jun 30, 2023 | -22.60 Mn |
| Mar 31, 2023 | -21.65 Mn |
| Dec 31, 2022 | -19.39 Mn |
| Sep 30, 2022 | -19.19 Mn |
| Jun 30, 2022 | -15.64 Mn |
| Mar 31, 2022 | -13.37 Mn |
| Dec 31, 2021 | -11.13 Mn |
| Sep 30, 2021 | -11.34 Mn |
| Jun 30, 2021 | -7.69 Mn |